Crisaborole

證據等級: L5

預測適應症: 10 個

Crisaborole: From Atopic Dermatitis to Exanthem

One-Sentence Summary

Crisaborole (Eucrisa®) is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor, FDA-approved since 2016 for the treatment of mild-to-moderate atopic dermatitis. The TxGNN model predicts it may be effective for Exanthem (skin rash/eruption), with 3 exploratory clinical trials but no published literature directly supporting this indication. The mechanistic rationale is plausible for certain inflammatory subtypes of exanthem, but direct clinical evidence is currently insufficient to support a repurposing decision.

Quick Overview

Item	Content
Original Indication	Atopic Dermatitis (mild to moderate)
Predicted New Indication	Exanthem (skin rash/eruption)
TxGNN Prediction Score	98.58%
Evidence Level	L4
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Crisaborole is a boron-containing small molecule that selectively inhibits phosphodiesterase 4 (PDE4), the enzyme responsible for degrading cyclic adenosine monophosphate (cAMP) in immune and epithelial cells. By blocking PDE4, crisaborole elevates intracellular cAMP, which in turn suppresses production of pro-inflammatory cytokines — principally IL-4, IL-13, and TNF-α. This Th2-skewed anti-inflammatory mechanism forms the pharmacological foundation of its established efficacy in atopic dermatitis, and provides a theoretical basis for treating other inflammatory skin conditions driven by overlapping cytokine pathways.

Exanthem is a broad clinical term describing widespread skin eruption, and its aetiology is highly heterogeneous — encompassing viral infections (e.g., roseola, measles), drug-induced reactions, and immune-mediated processes. When an exanthem is driven by Th2-dominant or cytokine-mediated inflammation — as may occur in drug-induced maculopapular rashes or EGFR inhibitor-related dermatological toxicity — PDE4 inhibition could theoretically modulate the local inflammatory cascade. Notably, the ongoing clinical trial NCT06118047 is evaluating crisaborole ointment specifically for Cetuximab-related skin toxicity in colorectal cancer patients, which represents precisely this type of drug-induced exanthem phenotype.

However, the heterogeneous aetiology of exanthem poses a fundamental challenge. Viral exanthems are largely self-limiting and driven by innate/adaptive immune responses to pathogens, where PDE4 inhibition has no established mechanistic role and could theoretically be counterproductive. The strong evidence base for crisaborole in atopic dermatitis (rank 2 indication; multiple completed Phase 3 RCTs across diverse populations) confirms the drug's anti-inflammatory skin profile and topical safety, but does not translate directly into efficacy across all forms of exanthem. Identifying a well-defined inflammatory exanthem subtype with PDE4/cAMP pathway involvement would be necessary before any repurposing program could be justified.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06118047	Phase 2	Unknown	33	Prospective single-arm study of crisaborole ointment BID for Cetuximab-related skin toxicity in metastatic colorectal cancer patients — the only trial directly addressing a drug-induced exanthem phenotype; small scale and status unconfirmed
NCT07352566	Phase 4	Not Yet Recruiting	10	Evaluating an in-situ cutaneous microdevice that delivers multiple approved topical medications (including crisaborole) directly to skin lesions in atopic dermatitis and psoriasis; crisaborole is one of several comparator agents, not the study focus
NCT03409367	N/A	Completed	1,260	Community-based observational study on skin care practices, allergies, and eczema; provides epidemiological background on inflammatory skin disease but contains no direct efficacy data for exanthem

Literature Evidence

Currently no related literature specifically addressing crisaborole in exanthem is available.

Singapore Market Information

Crisaborole is not currently registered with the Health Sciences Authority (HSA) of Singapore. There are no active product licences on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although PDE4 inhibition offers a biologically plausible mechanism for specific inflammatory subtypes of exanthem, current evidence is limited to three small or indirect exploratory trials and no published literature targeting this indication. The highly heterogeneous aetiology of exanthem makes it premature to define a viable patient population or clinical strategy without additional mechanistic and clinical characterisation.

To proceed, the following is needed:

Define a specific exanthem subtype where PDE4/Th2-mediated inflammation is the primary driver (e.g., EGFR inhibitor-induced acneiform rash, drug-induced maculopapular exanthem)
Await and review results from NCT06118047 (Cetuximab-related skin toxicity, Phase 2, n=33), which is the most directly relevant ongoing study
Commission preclinical or mechanistic studies to confirm PDE4 pathway involvement in the target exanthem subtype
Obtain full prescribing information (package insert warnings, contraindications) from the US Eucrisa label or equivalent regulatory document to enable safety screening
Assess HSA regulatory pathway for potential Singapore registration should evidence mature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.